StatOrigin open statistical archive
Industries Indicators Regions Rankings Compare Sources

Respiratory immunology and inflammation sales revenue (quarterly)

Quarterly sales revenue generated from respiratory, immunology, and inflammation pharmaceuticals.

Unit billion GBP Industry Pharmaceuticals

Cite & reuse Get this data as JSON
Records
1
Regions
1
Period
2026
Sources
1
Verification 1 verified data points Updated 17 Sep 2026 Last verified 17 Sep 2026 Next update Sources typically refresh quarterly

The chart

The figure

One published observation so far. A chart follows as soon as a second period is published.

Respiratory immunology and inflammation sales revenue (quarterly)

Global, Q2 2026

1 observation
1.1 billion GBP Global · Q2 2026 · GSK · full record
Source: GSK · CC BY 4.0 · statorigin.org

Every record

All records

1 record · 1 region · 2026

Download CSV JSON series
Respiratory immunology and inflammation sales revenue (quarterly): every record, grouped by region, newest first.
Period Value Source Type
Global 1 record
Q2 2026 1.1 billion GBP GSK · 30 Jun 2026 actual

Primary documents

Sources

1 document. Each links to the publisher's own copy.

Document Publisher Published Data points
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 GSK — 1

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Respiratory immunology and inflammation sales revenue (quarterly). Retrieved from https://statorigin.org/indicators/respiratory-immunology-and-inflammation-sales-revenue-quarterly

Download CSV Get this data as JSON Compare with… API docs